NCT03211234 - Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

January 31, 2020

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

2.0 mg DE-122 Injectable Solution + Lucentis

Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.

DRUG

4.0 mg DE-122 Injectable Solution + Lucentis

Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.

DRUG

Lucentis

Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.

Trial Locations (14)

33912

National Ophthalmic Research Institute, Fort Myers

57701

Black Hills Regional Eye Institute, Rapid City

77030

Retina Consultants of Houston, Houston

78503

Valley Retina Insititute, McAllen

78705

Retina Reseach Center, Austin

80401

Colorado Retina Associates, Golden

85296

Retina Research Institute, Gilbert

90211

Retina-Vitreous Associates, Beverly Hills

94040

Northern California Retina Vitreous Associates, Mountain View

94598

Bay Area Retina Associates, Walnut Creek

Unknown

Asian Eye Institute, Makati City

Peregrine Eye and Laser Institute, Makati City

The Medical City, Pasig

St. Luke's Medical center Quezon City, Quezon City

All Listed Sponsors

lead

Santen Inc.

INDUSTRY